Dedicated to the prevention & treatment of chronic inflammatory conditions
Chronic inflammation contributes to many of the largest and most serious conditions impacting our health today
It is estimated that in the United States alone half the population is affected by diseases associated with chronic inflammation. These conditions include heart disease, diabetes, arthritis, digestive disorders, asthma, allergies, eczema, psoriasis and many others.
Through our Gene Smart Nutrigenomics Discovery Platform, we examine the influence of natural bioactives on the expression of genes that control the inflammatory process. Utilizing this technology, we are developing a robust pipeline of patent-protected products for the prevention and treatment of targeted chronic inflammatory disorders in humans and animals. These products are designed for the Over-the-Counter (OTC), Functional Food & Beverage, and Veterinary Medical Food markets.
Our product platforms are brought to the U.S. and global markets through strategic partnerships with market leaders seeking to establish major new growth platforms.
Our first product was an OTC medical food for the dietary management of asthma based on a proprietary combination of natural fatty acids. We developed and tested the product through five clinical trials to validate safety and efficacy, and licensed it to Efficas, a Colorado-based consumer focused health-science and technology company (www.efficas.com).
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM